Neurology Updates

A challenge in preventing dementia lies in the ability to predict who may develop a neurodegenerative disease in advance of symptom presentation.

In patients with early AD, lecanemab, reduces brain amyloid levels and slows down cognitive decline by 27% over an 18 month period. However, it is…

Patients using angiotensin-II-stimulating antihypertensives have 45% lower risk to develop demenia compared to those that use…

Study results suggest that RO948 F 18 has a high specificity for Alzheimer disease–type tau and highlight its potential as a diagnostic marker.

Blood p-tau 181 is sensitive for identifying clinically diagnosed AD patients in the very early disease stages; differentiates AD from other…

Each AD phenotype had its own pattern of baseline and rates of change in tau pathology and grey matter loss, with some overlap particularly in the…

Rotigotine in patients with mild to moderate Alzheimer disease may have a potential effect in reducing frontal lobe cognitive dysfunction and in…

Dementia Lewy bodies (DLB) may present in the prodromal stage as mild cognitive impairment, delirium-onset or psychiatric-onset and authors proposed…

Dementia Lewy bodies (DLB) may present in the prodromal stage as mild cognitive impairment, delirium-onset or psychiatric-onset and authors proposed…

During the Covid-19 pandemic, most European countries have imposed personal restrictions on their populations in order to inhibit viral transmission…

Despite its large use, recommendations for the use of brain F-18 FDG-PET in clinical practice were still lacking. The European Academy of Neurology…

A recent study published in Journal of Alzheimer's Disease has found that most, but not all, patients in Sweden diagnosed with dementia have their…